NetraMark Bolsters Board with Pharmaceutical Veteran

NetraMark Holdings Inc., a clinical intelligence company, has strengthened its Board of Directors with the appointment of Dr. Keith M. Fournier, PhD, RAC. Dr. Fournier brings more than two decades of experience in pharmaceutical industry leadership, including drug development and regulatory strategy.

As Senior Vice President and Head of Regulatory Affairs at Abivax, Dr. Fournier leads the company's regulatory organization and strategy. His background spans senior positions at AbbVie, Merck KGaA, AstraZeneca, and Abivax, where he contributed to overall global regulatory organizational strategy.

NetraMark CEO George Achilleos believes Dr. Fournier will add significant value to the company as it expands its relationships with drug developers. 'He has spent more than 20 years inside some of the world's most sophisticated pharmaceutical organizations making decisions around regulatory strategy, clinical development, and the advancement of important therapeutic assets.'

Dr. Fournier commented on his new role: 'Clinical development continues to face a fundamental challenge in understanding heterogeneous patient populations and identifying the factors that influence treatment response. NetraMark is approaching this problem with a differentiated technology designed specifically around the realities of clinical trial data.'